Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



Collins Helen Louise Create: Alert

All | News | Filings
Date FiledTypeDescription
06/02/2023 4 Collins Helen Louise (Director) has filed a Form 4 on Kura Oncology, Inc.
Txns: Granted 26,000 options to buy @ $13.32, valued at $346.3k
02/27/2023 4 Collins Helen Louise (Chief Medical Officer) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns: Granted 287,084 options to buy @ $2.48, valued at $712k
06/23/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/29/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/19/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/26/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2020 4 Collins Helen Louise (EVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 11,583 shares @ $16.14, valued at $186.9k
Exercised 22,000 options to buy @ $0
11/13/2020 4 Collins Helen Louise (EVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 11,039 shares @ $18, valued at $198.7k
Exercised 22,000 options to buy @ $0
08/24/2020 4 Collins Helen Louise (EVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 827 shares @ $4.69, valued at $3.9k
03/23/2020 4 Collins Helen Louise (EVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 827 shares @ $2.3, valued at $1.9k
02/26/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/06/2020 4 Collins Helen Louise (EVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 5,345 shares @ $5.13, valued at $27.4k
09/04/2019 4 Collins Helen Louise (EVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 496 shares @ $5.43, valued at $2.7k
08/22/2019 4 Collins Helen Louise (EVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS, INC.
Txns: Granted 5,000 shares @ $0
Granted 20,000 options to buy @ $5.78, valued at $115.6k
06/26/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/07/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/02/2018 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/05/2018 4 Collins Helen Louise (SVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS INC
Txns: Paid exercise price by delivering 496 shares @ $14, valued at $6.9k
06/26/2018 4 Collins Helen Louise (SVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS INC
Txns: Paid exercise price by delivering 1,240 shares @ $17.38, valued at $21.6k
03/22/2018 4 Collins Helen Louise (SVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS INC
Txns: Paid exercise price by delivering 827 shares @ $16.26, valued at $13.4k
02/28/2018 4 Collins Helen Louise (SVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS INC
Txns: Paid exercise price by delivering 940 shares @ $31.24, valued at $29.4k
Granted 7,000 shares @ $0
Granted 50,000 options to buy @ $18.69, valued at $934.5k
02/07/2018 4 Collins Helen Louise (SVP and Chief Medical Officer) has filed a Form 4 on FIVE PRIME THERAPEUTICS INC
Txns: Paid exercise price by delivering 1,048 shares @ $18.42, valued at $19.3k
09/06/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/26/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
03/22/2017 4 Form 4 - Statement of changes in beneficial ownership of securities

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy